Blog

Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM. and B-cell response, inhibit DSA production, and remove circulating alloantibodies [2]. Circulating antibodies can be removed by therapeutic plasma exchange (TPE) [2]. It is widely believed that TPEs therapeutic benefit stems primarily from Fluticasone propionate HLA antibody removal [3]. However, TPE improves AMR-induced cardiac Fluticasone propionate allograft dysfunction in some but not all patients [4]. Limited data exist on which HLA antibodies may be most clinically significant in evaluating TPE response and thereby guide use of TPE for AMR treatment. CASE REPORT A 17-year-old male with familial dilated cardiomyopathy who underwent cardiac transplantation about 7 years prior to presentation was admitted for treatment of elevated DSA and decreased left ventricular ejection fraction (EF) of 53.6% (baseline in the 60s). Cardiac biopsy demonstrated International Society of Heart and Lung Transplantation (ISHLT) grade 2R cellular rejection with questionable C4d staining. He was treated with intravenous (IV) immune globulin and pulsed steroids. One month later, he developed worsening EF (42.3%) with increased proBNP (2,300 pg/mL; previously 1,150). He received a single dose of rituximab (375 mg/m2) and IV methylprednisolone (10 mg/kg) bid for 4 days. However, his condition deteriorated and he was transferred to the cardiac intensive care unit with worsening EF (now 35.2%) and increasing proBNP (6,807 pg/mL). IV furosemide and milrinone infusion were initiated. Cardiac biopsy showed ISHLT grade 0R with diffuse C4d staining, concerning for AMR. He initially underwent 5 consecutive days of TPE. All exchanges (1.0 C 2.0 plasma volumes) were performed with either 5% albumin or a combination of 5% albumin and fresh frozen plasma (when signs/symptoms of bleeding were present). TPE was followed by a standard protocol [5] consisting of pre-treatment with rituximab (375 mg/m2), which was then followed by treatment Rabbit Polyclonal to MSH2 with TPE, methylprednisolone (5 mg/kg), and bortezomib (1.3 mg/m2) on days 1, 4, 7, and 11. TPE was also performed as stand-alone therapy on days 14C16. Over the next 7 months, based on clinical improvement, TPE was weaned from every week (2 months), to every other week (3 months), to every three weeks (2 months). During this time, patient achieved EF in the 57C58% range by the 8th month of TPE. With TPE, there was initial decrease in the titer and mean fluorescent intensity of DSA. Anti-DR4 and anti-DR53 DSA resolved but anti-DQ8 persisted. Subsequently, based on the literature [6], a modified C1qScreen? assay (One Lambda, Canoga Park CA), which detects only the subset of HLA antibodies capable of binding human C1q with 100% sensitivity and specificity [6], was validated at Georgetown University Hospital Histocompatibility Laboratory. Assay results are typically available within 24 C 36 hours. Therefore, earlier serum samples were retroactively tested for C1q binding. C1q binding, which had been positive early in the clinical course, was found to have been negative during the last two months of TPE (See Figure). Therefore, TPE was held. Follow up cardiac biopsy showed that patient was negative for both cellular rejection and AMR. For 2 years following treatment, despite detectable anti DQ8 titers, which eventually resolved, the C1q assay remained negative. Three years later, patient is doing well with stable EF in the mid 60s. Open in a separate window Response of Ejection Fraction and Donor Specific Antibodies to Therapeutic Plasma Exchange.The horizontal axis shows treatment dates. The vertical axis shows the DQ8 donor specific antibody (DSA) titers while the vertical axis shows the antibody mean fluorescent intensity (MFI). The green arrows show when plasma exchange was done while the red arrows demonstrate C1q binding measurements. C1q binding became Fluticasone propionate negative about 2 months following initiation of treatment. Ejection fraction took time to gradually normalize. Anti DR4 and DR53 weakly positive titers (>1024) were last seen on 12/22 and 1/26 then 5/7, respectively. DISCUSSION Because much of the literature support is limited to retrospective case series and reports, AMR for pediatric cardiac transplantation remains an ASFA category III indication [3]. However, TPE is increasingly used for AMR management due to the high risk for allograft failure and mortality when cardiac transplant patients develop DSA [7]. One of the ways in which DSA causes endothelial damage and allograft injury is by activation of the complement cascade through complement fixation; however, not all DSA can fix complement [6]. Complement-fixing DSA may be important mediators of allograft injury [8] and can be identified by measurement of C1q.